股价一年暴涨超700%的Nanobiotix(NBTX.US)迎来收购催化强生(JNJ.US)有意出手

智通财经03-25

智通财经APP获悉，在法国知名刊物《La Lettre》报道称美国制药巨头强生(JNJ.US)正考虑提出收购交易，以收购一家法国癌症药物开发商之后，Nanobiotix(NBTX.US)股价周三在巴黎股市一度上涨约7%，在美股盘前交易中则一度上涨超15%。总部位于巴黎的Nanobiotix与全球医疗保健领军者强生目前保持合作关系，双方根据2023年与这家总部位于新泽西州的制药商强生签署的一项长期...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2622732570?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-25 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622732570","market":"fut","top_or_hot":-1,"title":"股价一年暴涨超700%的Nanobiotix(NBTX.US)迎来收购催化 强生(JNJ.US)有意出手","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，在法国知名刊物《La Lettre》报道称美国制药巨头强生(JNJ.US)正考虑提出收购交易，以收购一家法国癌症药物开发商之后，Nanobiotix(NBTX.US)股价周三在巴黎股市一度上涨约7%，在美股盘前交易中则一度上涨超15%。总部位于巴黎的Nanobiotix与全球医疗保健领军者强生目前保持合作关系，双方根据2023年与这家总部位于新泽西州的制药商强生签署的一项长期...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418954.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>股价一年暴涨超700%的Nanobiotix(NBTX.US)迎来收购催化 强生(JNJ.US)有意出手</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n股价一年暴涨超700%的Nanobiotix(NBTX.US)迎来收购催化 强生(JNJ.US)有意出手\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-25 20:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1418954.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，在法国知名刊物《La Lettre》报道称美国制药巨头强生(JNJ.US)正考虑提出收购交易，以收购一家法国癌症药物开发商之后，Nanobiotix(NBTX.US)股价周三在巴黎股市一度上涨约7%，在美股盘前交易中则一度上涨超15%。总部位于巴黎的Nanobiotix与全球医疗保健领军者强生目前保持合作关系，双方根据2023年与这家总部位于新泽西州的制药商强生签署的一项长期...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418954.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1418954.html","article_id":"2622732570","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622732570","pubTimestamp":1774440287,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"总部位于巴黎的Nanobiotix与全球医疗保健领军者强生目前保持合作关系，双方根据2023年与这家总部位于新泽西州的制药商强生签署的一项长期许可协议，共同开发并商业化其新一代核心资产JNJ-1900。在刚刚过去的2025年，Nanobiotix股价与市值涨幅已超过700%，使其最新的市值达到约15亿美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","JNJ":"强生","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU0070217475.USD":"JPM GLOBAL SELECT EQUITY \"A\" ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4534":"瑞士信贷持仓","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","BK4139":"生物科技","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4585":"ETF&股票定投概念","BK4592":"伊斯兰概念","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","NBTX":"NANOBIOTIX SPON ADS EACH REP 1 ORD SHS","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC"},"translate_title":"Nanobiotix (NBTX.US), whose share price has surged by more than 700% in a year, ushered in acquisition catalysis Johnson & Johnson (JNJ.US) intends to make a move","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBTX":1.5,"JNJ":1.5},"content_text":"智通财经APP获悉，在法国知名刊物《La Lettre》报道称美国制药巨头强生(JNJ.US)正考虑提出收购交易，以收购一家法国癌症药物开发商之后，Nanobiotix(NBTX.US)股价周三在巴黎股市一度上涨约7%，在美股盘前交易中则一度上涨超15%。总部位于巴黎的Nanobiotix与全球医疗保健领军者强生目前保持合作关系，双方根据2023年与这家总部位于新泽西州的制药商强生签署的一项长期许可协议，共同开发并商业化其新一代核心资产JNJ-1900(NBTXR3)。去年10月，该公司股价曾因一项1期临床试验的初步结果而大幅上涨;该试验旨在评估这种瘤内注射疗法，作为一种联合治疗方案的重要组成部分，用于一种名为局部晚期食管腺癌的食管癌。在刚刚过去的2025年，Nanobiotix股价与市值涨幅已超过700%，使其最新的市值达到约15亿美元。Nanobiotix本质上是一家法国晚期临床阶段肿瘤生物科技公司，核心不是做传统小分子或抗体药，而是做一种“物理机制驱动的纳米肿瘤治疗平台”。它最重要的核心资产是NBTXR3/JNJ-1900：这是一种由功能化氧化铪纳米颗粒构成的候选产品，通过一次性瘤内注射进入肿瘤后，在放疗照射下增强肿瘤内能量沉积，从而提高放疗杀伤肿瘤细胞的效率，同时尽量不增加周围正常组织的辐射损伤。该公司目前的主线业务，就是围绕这一“放疗增敏/放疗增强”大型平台，在头颈癌、肺癌、食管癌、胰腺癌等多个实体瘤中推进临床开发，并试图把它做成可跨癌种扩展的肿瘤治疗底层技术。2025年该公司可谓连续释放出积极临床信号，这也是该公司过去一年股价大涨700%的核心逻辑;例如食管癌 I 期初步数据显示治疗耐受性良好、13例患者中85% 疾病控制率、69%客观缓解率;该公司同期还在胰腺癌、肺癌等适应症上持续推进。2023 年强生旗下Janssen就与Nanobiotix签下了全球共同开发和商业化许可协议，2025年3月双方又修订协议，Nanobiotix不再承担关键 III 期头颈癌研究NANORAY-312的资金义务，现金可视期被延长到2026年年中，此举可谓显著缓解了临床型生物科技公司最致命的融资压力。若JNJ-1900资产或者III期头颈癌或后续多癌种数据继续正向，强生直接并购比长期分成更有利于掌握全球权益、定价权和后续适应症扩张，也就是说，Nanobiotix吸引强生的地方，不只是一个单品，而是它背后那套有潜力被放大为肿瘤放疗增强新范式的物理纳米治疗平台。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622732570","isCrawlerRequest":true}

股价一年暴涨超700%的Nanobiotix(NBTX.US)迎来收购催化 强生(JNJ.US)有意出手

精彩评论

股价一年暴涨超700%的Nanobiotix(NBTX.US)迎来收购催化强生(JNJ.US)有意出手